Bipolar Disorder (Manic Depression) – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) Market -
BIPOLAR DISORDER PIPELINE ANALYSIS
• Bipolar disorder, also known as manic-depression, is a mental illness that primarily affects mood. Symptoms of bipolar disorder are extreme irritability or agitation, a period of feeling empty, loss of interest in usual activities, sleep problems, etc.
• These disorders have different types of episodes such as manic episodes, hypomanic episodes, depressive episodes, and mixed episodes. Causes of bipolar disorders include childhood trauma, stressful life events, self-esteem problems, and genetic inheritance.
• People with bipolar disorder are also at higher risk of other diseases like thyroid disease, heart disease, diabetes, obesity, migraine headaches, and other physical illnesses.
• There is a range of treatments to control the disorder. As bipolar disorder is a lifelong and recurrent illness, people with the disease need prolonged treatment to maintain or control of bipolar symptoms. A potential maintenance treatment plan includes medication and psychotherapy.
• Medications such as valproic acid, lithium, and anticonvulsants are used to stabilize moods. Antidepressant medicines. Alternative treatments include Electroconvulsive Therapy (ECT) and herbal supplements.
• To pipeline of bipolar disorders includes a varied range of products, some of them are like Cyclurad – a combination of cycloserine/lurasidone of NeuroRx is in the Phase 3 stage of development. Sep-22 of Sumitomo Dannippon is in phase 2 whereas SEP-378608 of the same company is being developed in Phase 1 clinical trial. Prodrugs of the already existing marketed prodrugs have gained value, and products like KP303 (prodrug of quetiapine XR) is in the preclinical stage of development.
• Vraylar, an oral, once-daily atypical antipsychotic, was discovered and co-developed by Gedeon Richter and is licensed by Allergan in the US and Canada. For more than a decade both companies have conducted over 20 clinical trials enrolling thousands of patients worldwide to evaluate the efficacy and safety of cariprazine. Collaborated developments help to overcome the challenges of high costs.
• The growing need to curb the financial burden of bipolar disorder drives the growth prospects for the global bipolar disorder therapeutics market.
• It provides a comprehensive understanding of the emerging Phase III therapies for Bipolar Disorder (Manic Depression), which can turn out to be future, encouraging competitors for the marketed products. The complexity of bipolar disorder is yet to be answered.
• Demographics is expected to drive the growth of total prevalence in the forecasted period for bipolar I disorder and bipolar II disorder. Some of the significant factors responsible for the market’s growth are the high incidence of bipolar disorder symptoms in the US, the rising awareness about these disorders, the growing number of pipeline products, and the increasing prevalence of pediatric bipolar disorders.
• Bipolar disorder, also known as manic-depression, is a mental illness that primarily affects mood. Symptoms of bipolar disorder are extreme irritability or agitation, a period of feeling empty, loss of interest in usual activities, sleep problems, etc.
• These disorders have different types of episodes such as manic episodes, hypomanic episodes, depressive episodes, and mixed episodes. Causes of bipolar disorders include childhood trauma, stressful life events, self-esteem problems, and genetic inheritance.
• People with bipolar disorder are also at higher risk of other diseases like thyroid disease, heart disease, diabetes, obesity, migraine headaches, and other physical illnesses.
• There is a range of treatments to control the disorder. As bipolar disorder is a lifelong and recurrent illness, people with the disease need prolonged treatment to maintain or control of bipolar symptoms. A potential maintenance treatment plan includes medication and psychotherapy.
• Medications such as valproic acid, lithium, and anticonvulsants are used to stabilize moods. Antidepressant medicines. Alternative treatments include Electroconvulsive Therapy (ECT) and herbal supplements.
• To pipeline of bipolar disorders includes a varied range of products, some of them are like Cyclurad – a combination of cycloserine/lurasidone of NeuroRx is in the Phase 3 stage of development. Sep-22 of Sumitomo Dannippon is in phase 2 whereas SEP-378608 of the same company is being developed in Phase 1 clinical trial. Prodrugs of the already existing marketed prodrugs have gained value, and products like KP303 (prodrug of quetiapine XR) is in the preclinical stage of development.
• Vraylar, an oral, once-daily atypical antipsychotic, was discovered and co-developed by Gedeon Richter and is licensed by Allergan in the US and Canada. For more than a decade both companies have conducted over 20 clinical trials enrolling thousands of patients worldwide to evaluate the efficacy and safety of cariprazine. Collaborated developments help to overcome the challenges of high costs.
• The growing need to curb the financial burden of bipolar disorder drives the growth prospects for the global bipolar disorder therapeutics market.
• It provides a comprehensive understanding of the emerging Phase III therapies for Bipolar Disorder (Manic Depression), which can turn out to be future, encouraging competitors for the marketed products. The complexity of bipolar disorder is yet to be answered.
• Demographics is expected to drive the growth of total prevalence in the forecasted period for bipolar I disorder and bipolar II disorder. Some of the significant factors responsible for the market’s growth are the high incidence of bipolar disorder symptoms in the US, the rising awareness about these disorders, the growing number of pipeline products, and the increasing prevalence of pediatric bipolar disorders.
